Summary of Study ST001948
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001235. The data can be accessed directly via it's Project DOI: 10.21228/M82T49 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST001948 |
| Study Title | Metabolites Associated with Gestational Diabetes in Plasma |
| Study Type | Case:Control ancillary analysis of RCT |
| Study Summary | Gestational diabetes mellitus (GDM) significantly increases maternal and fetal health risks, but factors predictive of GDM are poorly understood. Plasma metabolomics analyses were conducted in early pregnancy to identify potential biomarkers for early prediction of Gestational Diabetes Mellitus (GDM). Sixty-eight pregnant women with overweight/obesity from a clinical trial of a lifestyle intervention were included. Participants who developed GDM (n=34; GDM group) were matched on treatment group, age, body mass index, and ethnicity with those who did not develop GDM (n=34; Non-GDM group). Blood draws were completed early in pregnancy (10-16 weeks). Plasma samples were analyzed by UPLC-MS using three metabolomics assays. |
| Institute | California Polytechnic State University |
| Department | Food Science and Nutrition |
| Laboratory | Cal Poly Metabolomics Service Center |
| Last Name | La Frano |
| First Name | Michael |
| Address | CALIFORNIA POLYTECHNIC STATE UNIVERSITY, 1 GRAND AVE |
| mlafrano@calpoly.edu | |
| Phone | 18057566233 |
| Submit Date | 2021-10-13 |
| Num Groups | 2 |
| Total Subjects | 68 |
| Num Females | 68 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML |
| Analysis Type Detail | LC-MS |
| Release Date | 2021-11-04 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001235 |
| Project DOI: | doi: 10.21228/M82T49 |
| Project Title: | Metabolites Associated with Gestational Diabetes in Plasma |
| Project Summary: | Gestational diabetes mellitus (GDM) significantly increases maternal and fetal health risks, but factors predictive of GDM are poorly understood. Plasma metabolomics analyses were conducted in early pregnancy to identify potential biomarkers for early prediction of Gestational Diabetes Mellitus (GDM). Sixty-eight pregnant women with overweight/obesity from a clinical trial of a lifestyle intervention were included. Participants who developed GDM (n=34; GDM group) were matched on treatment group, age, body mass index, and ethnicity with those who did not develop GDM (n=34; Non-GDM group). Blood draws were completed early in pregnancy (10-16 weeks). Plasma samples were analyzed by UPLC-MS using three metabolomics assays. |
| Institute: | Cal Poly St. Univ., San Luis Obispo |
| Department: | Food Science and Nutrition |
| Laboratory: | Cal Poly Metabolomics Service Center |
| Last Name: | La Frano |
| First Name: | Michael |
| Address: | CALIFORNIA POLYTECHNIC STATE UNIVERSITY, 1 GRAND AVE, SAN LUIS OBISPO, CA, 93407, USA |
| Email: | mlafrano@calpoly.edu |
| Phone: | 7143602022 |
| Funding Source: | NHLBI; HL114377, California State University Agricultural Research Institute 18-03-011, |
Subject:
| Subject ID: | SU002026 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Gender: | Female |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
| mb_sample_id | local_sample_id | Species | Case-Control | Time | Treatment (1=control, 2=treatment) |
|---|---|---|---|---|---|
| SA183796 | B39 | Human | GDM | 1st Trimester | 1 |
| SA183797 | B66 | Human | GDM | 1st Trimester | 1 |
| SA183798 | C39 | Human | GDM | 1st Trimester | 1 |
| SA183799 | B24 | Human | GDM | 1st Trimester | 1 |
| SA183800 | B8 | Human | GDM | 1st Trimester | 1 |
| SA183801 | B4 | Human | GDM | 1st Trimester | 1 |
| SA183802 | B33 | Human | GDM | 1st Trimester | 1 |
| SA183803 | C4 | Human | GDM | 1st Trimester | 1 |
| SA183804 | C12 | Human | GDM | 1st Trimester | 1 |
| SA183805 | C28 | Human | GDM | 1st Trimester | 1 |
| SA183806 | C17 | Human | GDM | 1st Trimester | 1 |
| SA183807 | B42 | Human | GDM | 1st Trimester | 1 |
| SA183808 | B57 | Human | GDM | 1st Trimester | 1 |
| SA183809 | C31 | Human | GDM | 1st Trimester | 1 |
| SA183810 | B54 | Human | GDM | 1st Trimester | 1 |
| SA183811 | C30 | Human | GDM | 1st Trimester | 1 |
| SA183812 | B12-REPAVG | Human | GDM | 1st Trimester | 1 |
| SA183813 | B23 | Human | GDM | 1st Trimester | 2 |
| SA183814 | B44 | Human | GDM | 1st Trimester | 2 |
| SA183815 | B62 | Human | GDM | 1st Trimester | 2 |
| SA183816 | B47 | Human | GDM | 1st Trimester | 2 |
| SA183817 | B40-REPAVG | Human | GDM | 1st Trimester | 2 |
| SA183818 | B18 | Human | GDM | 1st Trimester | 2 |
| SA183819 | B49 | Human | GDM | 1st Trimester | 2 |
| SA183820 | B7 | Human | GDM | 1st Trimester | 2 |
| SA183821 | C41 | Human | GDM | 1st Trimester | 2 |
| SA183822 | B25-REPAVG | Human | GDM | 1st Trimester | 2 |
| SA183823 | C32 | Human | GDM | 1st Trimester | 2 |
| SA183824 | B56 | Human | GDM | 1st Trimester | 2 |
| SA183825 | C24 | Human | GDM | 1st Trimester | 2 |
| SA183826 | C35 | Human | GDM | 1st Trimester | 2 |
| SA183827 | C2 | Human | GDM | 1st Trimester | 2 |
| SA183828 | C14 | Human | GDM | 1st Trimester | 2 |
| SA183829 | B53 | Human | GDM | 1st Trimester | 2 |
| SA183830 | C13 | Human | No_GDM | 1st Trimester | 1 |
| SA183831 | C20 | Human | No_GDM | 1st Trimester | 1 |
| SA183832 | C21 | Human | No_GDM | 1st Trimester | 1 |
| SA183833 | B65 | Human | No_GDM | 1st Trimester | 1 |
| SA183834 | C29 | Human | No_GDM | 1st Trimester | 1 |
| SA183835 | B29 | Human | No_GDM | 1st Trimester | 1 |
| SA183836 | C11 | Human | No_GDM | 1st Trimester | 1 |
| SA183837 | B60 | Human | No_GDM | 1st Trimester | 1 |
| SA183838 | B74 | Human | No_GDM | 1st Trimester | 1 |
| SA183839 | B70 | Human | No_GDM | 1st Trimester | 1 |
| SA183840 | B50 | Human | No_GDM | 1st Trimester | 1 |
| SA183841 | C40 | Human | No_GDM | 1st Trimester | 1 |
| SA183842 | B2 | Human | No_GDM | 1st Trimester | 1 |
| SA183843 | C18 | Human | No_GDM | 1st Trimester | 1 |
| SA183844 | B26 | Human | No_GDM | 1st Trimester | 1 |
| SA183845 | B21 | Human | No_GDM | 1st Trimester | 1 |
| SA183846 | B13 | Human | No_GDM | 1st Trimester | 1 |
| SA183847 | C23-REP AVG | Human | No_GDM | 1st Trimester | 2 |
| SA183848 | C43 | Human | No_GDM | 1st Trimester | 2 |
| SA183849 | B16 | Human | No_GDM | 1st Trimester | 2 |
| SA183850 | B5 | Human | No_GDM | 1st Trimester | 2 |
| SA183851 | B45 | Human | No_GDM | 1st Trimester | 2 |
| SA183852 | B69 | Human | No_GDM | 1st Trimester | 2 |
| SA183853 | B73 | Human | No_GDM | 1st Trimester | 2 |
| SA183854 | B51 | Human | No_GDM | 1st Trimester | 2 |
| SA183855 | B36 | Human | No_GDM | 1st Trimester | 2 |
| SA183856 | B67 | Human | No_GDM | 1st Trimester | 2 |
| SA183857 | B41 | Human | No_GDM | 1st Trimester | 2 |
| SA183858 | C10 | Human | No_GDM | 1st Trimester | 2 |
| SA183859 | C19 | Human | No_GDM | 1st Trimester | 2 |
| SA183860 | C1-REPAVG | Human | No_GDM | 1st Trimester | 2 |
| SA183861 | B34 | Human | No_GDM | 1st Trimester | 2 |
| SA183862 | B55 | Human | No_GDM | 1st Trimester | 2 |
| SA183863 | C5 | Human | No_GDM | 1st Trimester | 2 |
| Showing results 1 to 68 of 68 |
Collection:
| Collection ID: | CO002019 |
| Collection Summary: | Blood samples (plasma) were collected from participants with GDM and non-GDM affected pregnancies during 10-16 weeks gestation (GDM for GDM cases and Non-GDM for control cases). |
| Collection Protocol Filename: | La_Frano_Lab_Methods_Doc_v8.pdf |
| Sample Type: | Blood (plasma) |
Treatment:
| Treatment ID: | TR002038 |
| Treatment Summary: | This was a secondary analysis using samples from the Healthy Beginnings/Comienzos Saludables Study, a randomized clinical trial (RCT) that is part of the Lifestyle Interventions for Expectant Moms (LIFE-Moms) Consortium (Phelan et al., 2018). This RCT focused on the outcomes of behavior lifestyle change on weight gain during gestation. Samples were acquired from two study sites: California Polytechnic State University, San Luis Obispo, California and Miriam Hospital with Women and Infants Hospital in Providence, Rhode Island. This trial was registered as NCT01545934. Eligibility consisted of being 9-16 weeks gestational age, BMI (in kg/m2) ≥ 25 upon study entry height and weight, English or Spanish speaking, age ≥ 18 years old, and singleton pregnancy. Participants were excluded if glycated hemoglobin ≥ 6.5, reported major health diseases, substance abuse, undergoing treatment for serious psychological disorders, had contradictions to aerobic exercise, or who had repeated no-shows or loss of contact during screening. Participants were randomly assigned to two different intervention methods. Group one received enhanced usual care, which represented the control group. Group two had a multi-component lifestyle intervention, which included diet, exercise, and behavioral change. Data was collected throughout pregnancy, including blood samples, diet assessment, and clinic measured GDM diagnosis. Blood samples were taken between gestational weeks 10-16. Since the multi-component lifestyle intervention showed no statistically significant effect on GDM occurrence (p=0.7) (Phelan et al., 2018), the samples used for this secondary analysis are from both the control and treatment groups. There were a total of 34 GDM cases that were collected from the California (n=13) and Rhode Island (n=21) study sites. Samples for 34 GDM cases were matched to 34 healthy controls prior to metabolomics analysis based on age, study entry body mass index (BMI), ethnicity, study site, and treatment. The two groups did not differ in weight gain from entry to 26 weeks. |
| Treatment Protocol Filename: | La_Frano_Treatment_Protocol_v1.pdf |
Sample Preparation:
| Sampleprep ID: | SP002032 |
| Sampleprep Summary: | 1. 25 µL of plasma were added to 1.5 mL tubes before the addition of 10 µL of 1 µM internal standard solution, followed by 750 µL chilled methanol. 2. Samples were vortexed 30 seconds prior to being centrifuged at 15,000 x G for 10 min. 3. The supernatant was transferred to 1.5 mL high performance liquid chromatography (HPLC) amber glass vials, dried by centrifugal vacuum evaporation, and reconstituted in 100 µL 3:1 acetonitrile:methanol solution with an internal standard [12-[(cyclohexylamino) carbonyl]amino]-dodecanoic acid (CUDA)] solution. 4.The reconstituted solution was vortexed 30 seconds and placed on ice for 10 minutes. 5. The solution was then centrifuged at 10,000 x G for 3 minutes after being transferred to microfilter tubes. 6. The supernatant was transferred to a HPLC vial to be analyzed using the UPLC-MS. |
| Sampleprep Protocol Filename: | La_Frano_Lab_Methods_Doc_v8.pdf |
Combined analysis:
| Analysis ID | AN003170 | AN003171 | AN003172 |
|---|---|---|---|
| Analysis type | MS | MS | MS |
| Chromatography type | HILIC | HILIC | Reversed phase |
| Chromatography system | Waters Acquity I-Class | Waters Acquity I-Class | Waters Acquity I-Class |
| Column | Phenomenex Luna NH2 (150 x 2.1mm,3um) | Waters Atlantis HILIC (150 x 2.1mm,3um) | Grace Prosphere HP C4 (150 x 3mm,3um) |
| MS Type | ESI | ESI | ESI |
| MS instrument type | QTRAP | QTRAP | QTRAP |
| MS instrument name | ABI Sciex 4000 QTrap | ABI Sciex 4000 QTrap | ABI Sciex 4000 QTrap |
| Ion Mode | NEGATIVE | POSITIVE | POSITIVE |
| Units | Peak Area | Peak Area | Peak Area |
Chromatography:
| Chromatography ID: | CH002343 |
| Methods Filename: | La_Frano_Lab_Methods_Doc_v8.pdf |
| Instrument Name: | Waters Acquity I-Class |
| Column Name: | Phenomenex Luna NH2 (150 x 2.1mm,3um) |
| Chromatography Type: | HILIC |
| Chromatography ID: | CH002344 |
| Methods Filename: | La_Frano_Lab_Methods_Doc_v8.pdf |
| Instrument Name: | Waters Acquity I-Class |
| Column Name: | Waters Atlantis HILIC (150 x 2.1mm,3um) |
| Chromatography Type: | HILIC |
| Chromatography ID: | CH002345 |
| Methods Filename: | La_Frano_Lab_Methods_Doc_v8.pdf |
| Instrument Name: | Waters Acquity I-Class |
| Column Name: | Grace Prosphere HP C4 (150 x 3mm,3um) |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS002948 |
| Analysis ID: | AN003170 |
| Instrument Name: | ABI Sciex 4000 QTrap |
| Instrument Type: | QTRAP |
| MS Type: | ESI |
| MS Comments: | Please see lab methods file. |
| Ion Mode: | NEGATIVE |
| Acquisition Parameters File: | La_Frano_Lab_Methods_Doc_v8.pdf |
| Processing Parameters File: | La_Frano_Lab_Methods_Doc_v8.pdf |
| Analysis Protocol File: | La_Frano_Lab_Methods_Doc_v8.pdf |
| MS ID: | MS002949 |
| Analysis ID: | AN003171 |
| Instrument Name: | ABI Sciex 4000 QTrap |
| Instrument Type: | QTRAP |
| MS Type: | ESI |
| MS Comments: | Please see lab methods file. |
| Ion Mode: | POSITIVE |
| Acquisition Parameters File: | La_Frano_Lab_Methods_Doc_v8.pdf |
| Processing Parameters File: | La_Frano_Lab_Methods_Doc_v8.pdf |
| Analysis Protocol File: | La_Frano_Lab_Methods_Doc_v8.pdf |
| MS ID: | MS002950 |
| Analysis ID: | AN003172 |
| Instrument Name: | ABI Sciex 4000 QTrap |
| Instrument Type: | QTRAP |
| MS Type: | ESI |
| MS Comments: | Please see lab methods file. |
| Ion Mode: | POSITIVE |
| Acquisition Parameters File: | La_Frano_Lab_Methods_Doc_v8.pdf |
| Processing Parameters File: | La_Frano_Lab_Methods_Doc_v8.pdf |
| Analysis Protocol File: | La_Frano_Lab_Methods_Doc_v8.pdf |
